NEW YORK (GenomeWeb News) – PerkinElmer's third quarter revenues increased 3 percent year over year, the firm reported after the close of the market on Wednesday.

For the three months ended Sept. 29, total revenues rose to $524.3 million from $509.6 million a year ago. Analysts, on average, expected revenues of $523.8 million.

On an organic basis, revenues rose 2 percent year over year, PerkinElmer Chairman and CEO Robert Friel said on a conference call following the release of the results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.